Company Filing History:
Years Active: 2019-2021
Title: The Innovations of Jérôme Charles Sarie
Introduction
Jérôme Charles Sarie is a notable inventor based in Basel, Switzerland. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds aimed at treating various neurological conditions. With a total of 3 patents, his work has the potential to impact the lives of many individuals suffering from debilitating diseases.
Latest Patents
Sarie's latest patents include innovative compounds designed for therapeutic applications. The first patent, titled "Bicyclic heteroaryl derivatives," relates to a compound of formula I, which may be used for the treatment of Alzheimer's disease, cerebral amyloid angiopathy, hereditary cerebral hemorrhage with amyloidosis, Dutch-type (HCHWA-D), multi-infarct dementia, dementia pugilistica, or Down syndrome. The compound features various substituents, including hydrogen, lower alkyl, halogen, and lower alkoxy groups.
The second patent, "Bridged piperidine derivatives," also focuses on compounds that may be utilized for similar therapeutic purposes. This invention describes a compound of formula (I) with various substituents and highlights its potential in treating the same neurological conditions as the first patent.
Career Highlights
Throughout his career, Jérôme Charles Sarie has worked with prominent companies in the pharmaceutical industry, including Hoffmann-La Roche Inc. and F. Hoffmann-La Roche AG. His experience in these organizations has contributed to his expertise in drug development and innovation.
Collaborations
Sarie has collaborated with notable colleagues, including Bjoern Bartels and Roland Jakob-Roetne. These partnerships have likely enhanced his research and development efforts, leading to the successful creation of his patented compounds.
Conclusion
Jérôme Charles Sarie is a distinguished inventor whose work in pharmaceuticals has the potential to advance treatments for serious neurological disorders. His innovative patents reflect a commitment to improving patient outcomes and addressing critical health challenges.